Aurobindo Pharma receives USFDA Approval for Mometasone Furoate Monohydrate Nasal Spray 50 mcg/spray

Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nasonex Nasal Spray, 50 mcg/spray of Organon LLC. The product will be launched in Q1FY25.

The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024, according to IQVIA. Aurobindo now has a total of 507 ANDA approvals (488 Final approvals and 19 tentative approvals) from USFDA.

Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and paediatric patients 2 years of age and older.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 989.40 as compared to the previous close of Rs. 1017.45. The total number of shares traded during the day was 16980 in over 1293 trades.

The stock hit an intraday high of Rs. 1017.45 and intraday low of 986.25. The net turnover during the day was Rs. 16965862.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 USFDA FinalApproval MometasoneFuroateMonohydrate NasalSpray